ofloxacin has been researched along with Helicobacter Infections in 149 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Helicobacter Infections: Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to evaluate the efficacy and tolerability of a levofloxacin-based regimen in patients with peptic ulcer after failure of the standard first-line H." | 9.15 | Second-line levofloxacin-based triple therapy's efficiency for Helicobacter pylori eradication in patients with peptic ulcer. ( Akyuz, F; Ermis, F; Kaymakoglu, S; Kurt, R; Mungan, Z; Nazik, H; Pinarbasi, B; Uyanikoglu, A, 2011) |
| "Levofloxacin may be effective for treatment of rectal lymphoma of mucosa-associated lymphoid tissue regardless of Helicobacter pylori infection." | 5.32 | Regression of rectal mucosa-associated lymphoid tissue lymphoma but persistence of Helicobacter pylori infection of gastric mucosa after administration of levofloxacin: report of a case. ( Dohden, K; Hattori, M; Hayashi, H; Hosokawa, O; Kaizaki, Y, 2004) |
| " The aim of this study was to evaluate the efficacy and tolerability of a levofloxacin-based regimen in patients with peptic ulcer after failure of the standard first-line H." | 5.15 | Second-line levofloxacin-based triple therapy's efficiency for Helicobacter pylori eradication in patients with peptic ulcer. ( Akyuz, F; Ermis, F; Kaymakoglu, S; Kurt, R; Mungan, Z; Nazik, H; Pinarbasi, B; Uyanikoglu, A, 2011) |
| " Two groups exhibited similar adverse event rates (AEA 14." | 3.11 | Efficacy and Safety of Antofloxacin-Based Triple Therapy for Helicobacter pylori Eradication Failure in China. ( He, XJ; Jiang, CS; Li, DZ; Liu, G; Wang, W; Zeng, XP, 2022) |
| " The total incidence of adverse events during the eradication therapy did not significantly differ between the ACLA and LCLA groups (31." | 3.01 | Antofloxacin-based bismuth quadruple therapy is safe and effective in Helicobacter pylori eradication: A prospective, open-label, randomized trial. ( He, XJ; Jiang, CS; Li, DZ; Liu, G; Wang, W; Zeng, XP, 2021) |
| "Levofloxacin resistance was present in 30." | 2.78 | Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. ( Graham, DY; Liang, X; Liao, J; Liu, W; Lu, H; Sun, Q; Xiao, S; Zhang, W; Zheng, Q, 2013) |
| "Levofloxacin-based treatment for H." | 2.77 | Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line Helicobacter pylori eradication: a single-blind randomized clinical trial. ( Aresti-Zárate, S; Ayestarán, B; Campos, MR; Carrascosa, MF; Cobo, M; Cuadrado-Lavín, A; Dierssen-Sotos, T; Fernández-Pousa, A; González-Colominas, E; Hernández, M; Pascual, EL; Salcines-Caviedes, JR, 2012) |
| " There was no difference among the treatment groups with regard to the incidence and severity of adverse events reported." | 2.75 | Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study. ( Abdelfatah, M; Assem, M; El Azab, G; Rasheed, MA; Shastery, M, 2010) |
| "Levofloxacin-250 therapy was cost-saving compared with clarithromycin sequential therapy." | 2.75 | Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. ( Cuomo, A; Federico, A; Gravina, AG; Iovene, MR; Marmo, R; Miranda, A; Nardone, G; Rocco, A; Romano, M; Salerno, R; Sica, M; Tiso, A, 2010) |
| " However, dosage and length of levofloxacin-based regimens have not been established." | 2.74 | Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication. ( Di Caro, S; Franceschi, F; Gasbarrini, A; La Rocca, E; Mariani, A; Masci, E; Raimondo, D; Testoni, A; Thompson, F, 2009) |
| " Subsequent studies should be performed to evaluate antibiotic resistance, doses, dosing intervals, duration of treatment, and safety of these two regimes." | 2.73 | Failure of Helicobacter pylori treatment after regimes containing clarithromycin: new practical therapeutic options. ( Coelho, L; Moretzsohn, L; Sanches, B; Vieira, G, 2008) |
| " pylori treatment: effectiveness (>80%), simplicity (twice-daily dosing and excellent compliance) and safety (low incidence of adverse effects)." | 2.73 | First-line triple therapy with levofloxacin for Helicobacter pylori eradication. ( Fernández-Bermejo, M; Gisbert, JP; González-García, G; Mateos-Rodríguez, JM; Molina-Infante, J; Pérez-Gallardo, B; Prieto-Bermejo, AB; Robledo-Andrés, P, 2007) |
| "Clarithromycin resistance was indirectly assessed by the (13)C-urea breath test, with a post-treatment value cut-off point at 15." | 2.73 | Levofloxacin-containing triple therapy to eradicate the persistent H. pylori after a failed conventional triple therapy. ( Chang, WL; Chen, WY; Cheng, HC; Sheu, BS; Wu, JJ; Yang, HB, 2007) |
| " The aim of the present study was to assess the efficacy of rifaximin, a poorly absorbed antibiotic, for H." | 2.72 | Rifaximin-based regimens for eradication of Helicobacter pylori: a pilot study. ( Cammarota, G; Candelli, M; Cazzato, A; Finizio, R; Gabrielli, M; Gasbarrini, A; Gasbarrini, G; Lauritano, EC; Nista, EC; Ojetti, V; Santoro, M; Zocco, MA, 2006) |
| "Rabeprazole is a proton pump inhibitor which is particularly suitable for use in short-term Helicobacter pylori eradication treatment." | 2.72 | Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole. ( Bilardi, C; Dulbecco, P; Giannini, EG; Mamone, M; Mansi, C; Santi, ML; Savarino, V; Testa, R, 2006) |
| "Levofloxacin has been shown to be effective in Helicobacter pylori eradication." | 2.71 | Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. ( Cammarota, G; Candelli, M; Carloni, E; Cazzato, IA; Cremonini, F; Di Caro, S; Gabrielli, M; Gasbarrini, A; Gasbarrini, G; Nista, EC; Ojetti, V; Santarelli, L; Zocco, MA, 2003) |
| "Clarithromycin resistance was detected in all of 8 (100%) RLC-1 failures and in 1 out of 3 (33%) RLC-2 failures." | 2.71 | High-dose versus low-dose clarithromycin in 1-week triple therapy, including rabeprazole and levofloxacin, for Helicobacter pylori eradication. ( Branca, G; Cammarota, G; Cannizzaro, O; Cesaro, P; Cianci, R; di Caro, S; Fedeli, P; Gasbarrini, G; Lecca, PG; Martino, A, 2004) |
| "The aim was to confirm which was the better regimen for second-line therapy after treatment failure with a standard triple therapy in Japan, a high dosage of levofloxacin- or metronidazole-based therapy." | 2.71 | Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan. ( Aoyama, N; Kasuga, M; Matsumoto, Y; Miki, I; Mitani, T; Miyachi, H; Morita, Y; Shirasaka, D; Tamura, T; Toyoda, M; Watanabe, Y, 2005) |
| "As clarithromycin is a key antibiotic in the eradication of H." | 2.49 | A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). ( Gisbert, JP; Marin, AC; McNicholl, AG, 2013) |
| "000), had lower side effect rate than standard triple therapy (total OR = 0." | 2.44 | [Effectiveness and safety of proton pump inhibitor and levofloxacin based first-line triple therapy in the eradication of Helicobacter pylori: a meta-analysis]. ( Liu, LN; Zhang, ZF; Zhao, G, 2008) |
| " dosing of levofloxacin (81%[95% CI: 78%-89%]vs 84%[95% CI: 66%-97%])." | 2.43 | Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. ( Chey, WD; Kim, HM; Saad, RJ; Schoenfeld, P, 2006) |
| "Clarithromycin resistance was associated with macrolide use for any indication during the previous year (p = 0." | 1.36 | Antibiotic resistance of Helicobacter pylori in Israeli children. ( Levy, I; Samra, Z; Shmuely, H; Yahav, J; Zevit, N, 2010) |
| " For eradication, European, Canadian, and American guidelines recommend a regimen consisting of a proton pump inhibitor, clarithromycin, and metronidazole or amoxicillin dosed twice daily for at least 7 days." | 1.35 | An alternative salvage regimen for Helicobacter pylori-resistant patients with heart failure. ( Cantu, M; Ferguson, D; Page, RL, 2008) |
| "Levofloxacin resistance was associated with any prior fluoroquinolone use over the previous 10 years and with the total number of fluoroquinolone courses prescribed (P<." | 1.34 | The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection. ( Bensler, M; Bruce, MG; Carothers, JJ; Coleman, JM; Hennessy, TW; Hurlburt, DA; McMahon, BJ; Morris, JM; Parkinson, AJ; Reasonover, AL, 2007) |
| "Levofloxacin resistance was also more frequent in those strains with either clarithromycin or metronidazole resistance." | 1.34 | Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. ( Hassan, C; Morini, S; Perna, F; Ricci, C; Saracino, I; Vaira, D; Zullo, A, 2007) |
| "Levofloxacin has been proposed as an alternative to classic therapy in secondary resistance to Helicobacter pylori." | 1.33 | Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole. ( Capodicasa, S; Cappello, G; Coraggio, D; Grossi, L; Marzio, L, 2006) |
| "Levofloxacin may be effective for treatment of rectal lymphoma of mucosa-associated lymphoid tissue regardless of Helicobacter pylori infection." | 1.32 | Regression of rectal mucosa-associated lymphoid tissue lymphoma but persistence of Helicobacter pylori infection of gastric mucosa after administration of levofloxacin: report of a case. ( Dohden, K; Hattori, M; Hayashi, H; Hosokawa, O; Kaizaki, Y, 2004) |
| "Levofloxacin has been proposed as an alternative for these refractory infections." | 1.32 | High levels of dual resistance to clarithromycin and metronidazole and in vitro activity of levofloxacin against Helicobacter pylori isolates from patients after failure of therapy. ( Branca, G; Cammarota, G; Fadda, G; Gasbarrini, A; Gasbarrini, GB; Schito, AM; Spanu, T, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.67) | 18.2507 |
| 2000's | 73 (48.99) | 29.6817 |
| 2010's | 73 (48.99) | 24.3611 |
| 2020's | 2 (1.34) | 2.80 |
| Authors | Studies |
|---|---|
| He, XJ | 2 |
| Zeng, XP | 2 |
| Jiang, CS | 2 |
| Liu, G | 2 |
| Li, DZ | 2 |
| Wang, W | 2 |
| Matsumoto, T | 1 |
| Inokuma, T | 1 |
| Imai, Y | 1 |
| Marin, AC | 1 |
| McNicholl, AG | 1 |
| Gisbert, JP | 14 |
| Liao, J | 1 |
| Zheng, Q | 2 |
| Liang, X | 2 |
| Zhang, W | 1 |
| Sun, Q | 1 |
| Liu, W | 1 |
| Xiao, S | 1 |
| Graham, DY | 3 |
| Lu, H | 3 |
| Calhan, T | 1 |
| Kahraman, R | 1 |
| Sahin, A | 1 |
| Senates, E | 1 |
| Doganay, HL | 1 |
| Kanat, E | 1 |
| Ozdil, K | 1 |
| Sokmen, HM | 1 |
| Mohammadzadeh, R | 1 |
| Ahmadiyan, N | 1 |
| Song, M | 1 |
| Ang, TL | 1 |
| Zamani, M | 1 |
| Shokri-Shirvani, J | 1 |
| Zamani, V | 1 |
| Jung, HS | 1 |
| Shim, KN | 1 |
| Baik, SJ | 1 |
| Na, YJ | 1 |
| Kang, MJ | 1 |
| Jung, JM | 1 |
| Ha, CY | 1 |
| Jung, SA | 1 |
| Yoo, K | 1 |
| Romano, M | 3 |
| Iovene, MR | 3 |
| Russo, MI | 1 |
| Rocco, A | 3 |
| Salerno, R | 2 |
| Cozzolino, D | 1 |
| Pilloni, AP | 1 |
| Tufano, MA | 1 |
| Vaira, D | 8 |
| Nardone, G | 3 |
| Hagymási, K | 1 |
| Tulassay, Z | 1 |
| Di Caro, S | 5 |
| Franceschi, F | 1 |
| Mariani, A | 1 |
| Thompson, F | 1 |
| Raimondo, D | 1 |
| Masci, E | 1 |
| Testoni, A | 1 |
| La Rocca, E | 1 |
| Gasbarrini, A | 9 |
| Zhang, ZF | 1 |
| Zhao, G | 1 |
| Liu, LN | 1 |
| Sanches, B | 1 |
| Coelho, L | 1 |
| Moretzsohn, L | 1 |
| Vieira, G | 1 |
| Kuo, CH | 2 |
| Hu, HM | 2 |
| Kuo, FC | 2 |
| Hsu, PI | 7 |
| Chen, A | 2 |
| Yu, FJ | 2 |
| Tsai, PY | 1 |
| Wu, IC | 1 |
| Wang, SW | 1 |
| Li, CJ | 1 |
| Weng, BC | 1 |
| Chang, LL | 1 |
| Jan, CM | 1 |
| Wang, WM | 1 |
| Wu, DC | 7 |
| Schrauwen, RW | 1 |
| Janssen, MJ | 1 |
| de Boer, WA | 1 |
| Eisig, JN | 1 |
| Silva, FM | 1 |
| Barbuti, RC | 1 |
| Rodriguez, TN | 1 |
| Malfertheiner, P | 2 |
| Moraes Filho, JP | 1 |
| Zaterka, S | 1 |
| Chang, WL | 2 |
| Sheu, BS | 2 |
| Cheng, HC | 2 |
| Yang, YJ | 1 |
| Yang, HB | 2 |
| Wu, JJ | 2 |
| Pérez-Aisa, A | 4 |
| Castro-Fernández, M | 4 |
| Barrio, J | 3 |
| Rodrigo, L | 3 |
| Cosme, A | 4 |
| Gisbert, JL | 3 |
| Marcos, S | 3 |
| Moreno-Otero, R | 3 |
| Katelaris, PH | 2 |
| Selgrad, M | 1 |
| Kandulski, A | 1 |
| Hung, IF | 1 |
| Chan, P | 2 |
| Leung, S | 1 |
| Chan, FS | 1 |
| Hsu, A | 2 |
| But, D | 2 |
| Seto, WK | 1 |
| Wong, SY | 1 |
| Chan, CK | 4 |
| Gu, Q | 3 |
| Tong, TS | 2 |
| Cheung, TK | 2 |
| Chu, KM | 3 |
| Wong, BC | 4 |
| Aydin, A | 1 |
| Oruc, N | 1 |
| Turan, I | 1 |
| Ozutemiz, O | 1 |
| Tuncyurek, M | 1 |
| Musoglu, A | 1 |
| Pontone, S | 1 |
| Standoli, M | 1 |
| Angelini, R | 1 |
| Pontone, P | 1 |
| Zullo, A | 12 |
| Hassan, C | 10 |
| Cristofari, F | 2 |
| Iegri, C | 1 |
| De Francesco, V | 8 |
| Molina-Infante, J | 3 |
| Perez-Gallardo, B | 2 |
| Fernandez-Bermejo, M | 5 |
| Hernandez-Alonso, M | 1 |
| Vinagre, G | 1 |
| Dueñas, C | 1 |
| Mateos-Rodriguez, JM | 2 |
| Gonzalez-Garcia, G | 2 |
| Abadia, EG | 1 |
| Zevit, N | 1 |
| Levy, I | 1 |
| Shmuely, H | 2 |
| Samra, Z | 2 |
| Yahav, J | 2 |
| Suzuki, H | 1 |
| Nishizawa, T | 1 |
| Hibi, T | 1 |
| Cheng, H | 1 |
| Hu, FL | 1 |
| Zhang, GX | 2 |
| Shi, RH | 2 |
| Du, YQ | 1 |
| Li, ZS | 1 |
| Han, W | 1 |
| Li, YQ | 1 |
| Wu, QD | 1 |
| Qian, KD | 1 |
| Krystallis, C | 1 |
| Kamberoglou, D | 1 |
| Pistiolas, D | 2 |
| Anifanti, C | 1 |
| Koutsoumbas, A | 1 |
| Doulgeroglou, V | 1 |
| Tzias, V | 1 |
| Liou, JM | 4 |
| Lin, JT | 5 |
| Chang, CY | 4 |
| Chen, MJ | 4 |
| Cheng, TY | 1 |
| Lee, YC | 4 |
| Chen, CC | 4 |
| Sheng, WH | 3 |
| Wang, HP | 4 |
| Wu, MS | 5 |
| D'Ercole, C | 1 |
| Erçin, CN | 1 |
| Uygun, A | 2 |
| Toros, AB | 1 |
| Kantarcioğlu, M | 2 |
| Kilciler, G | 1 |
| Polat, Z | 2 |
| Bağci, S | 1 |
| Manes, G | 2 |
| Scaccianoce, G | 2 |
| Assem, M | 1 |
| El Azab, G | 1 |
| Rasheed, MA | 1 |
| Abdelfatah, M | 1 |
| Shastery, M | 1 |
| Li, Y | 2 |
| Huang, X | 1 |
| Yao, L | 2 |
| Shi, R | 2 |
| Zhang, G | 2 |
| Yang, JC | 1 |
| Lee, PI | 1 |
| Hsueh, PR | 1 |
| Pajares, JM | 3 |
| Chen, LW | 1 |
| Chien, RN | 1 |
| Chang, JJ | 1 |
| Fang, KM | 1 |
| Chang, LC | 1 |
| Cuomo, A | 1 |
| Gravina, AG | 2 |
| Miranda, A | 2 |
| Tiso, A | 1 |
| Sica, M | 1 |
| Marmo, R | 2 |
| Federico, A | 2 |
| Konno, T | 1 |
| Motoori, S | 1 |
| Iwamoto, N | 1 |
| Miyazawa, T | 1 |
| Saito, S | 1 |
| Kitagawa, N | 1 |
| Saisho, H | 1 |
| Furuse, J | 1 |
| Itabashi, M | 1 |
| Sun, QJ | 1 |
| Gu, WQ | 1 |
| Liu, WZ | 1 |
| Xiao, SD | 1 |
| Pan, X | 1 |
| Qiu, Y | 1 |
| Tang, Q | 1 |
| Qian, B | 1 |
| Wang, YC | 1 |
| Hung, HW | 1 |
| Chian, H | 1 |
| Chang, SC | 1 |
| Lochmannová, J | 1 |
| Ono, M | 1 |
| Ohnishi, S | 1 |
| Onishi, R | 1 |
| Takahashi, S | 1 |
| Kobayashi, Y | 1 |
| Suzuki, M | 1 |
| Kubo, K | 1 |
| Dazai, M | 1 |
| Yamamoto, J | 1 |
| Oda, H | 1 |
| Tada, K | 1 |
| Takahashi, T | 1 |
| Miyagishima, T | 1 |
| Talebi Bezmin Abadi, A | 1 |
| Ghasemzadeh, A | 1 |
| Taghvaei, T | 1 |
| Mobarez, AM | 1 |
| Kim, JY | 1 |
| Kim, NY | 1 |
| Kim, SJ | 1 |
| Baik, GH | 1 |
| Kim, GH | 1 |
| Kim, JM | 2 |
| Nam, RH | 1 |
| Kim, HB | 1 |
| Lee, DH | 1 |
| Jung, HC | 2 |
| Song, IS | 2 |
| Goh, KL | 1 |
| Navaratnam, P | 1 |
| Güzelbulut, F | 1 |
| Sezikli, M | 1 |
| Akkan Çetinkaya, Z | 1 |
| Erhan Altunöz, M | 1 |
| Günes, P | 1 |
| Düzgün, S | 1 |
| Ovünç Kurdas, O | 1 |
| Fang, YJ | 2 |
| Lee, JY | 2 |
| Choi, KH | 1 |
| Chung, WC | 1 |
| Lee, KM | 1 |
| Paik, CN | 1 |
| Kim, EJ | 1 |
| Kang, BK | 1 |
| Oak, JH | 1 |
| Jung, SH | 1 |
| Yamamoto, T | 1 |
| Takano, T | 1 |
| Higuchi, W | 1 |
| Nishiyama, A | 1 |
| Taneike, I | 1 |
| Yoshida, K | 1 |
| Kanda, H | 1 |
| Imamura, Y | 1 |
| Misselwitz, B | 1 |
| Kaiser, P | 1 |
| Bauerfeind, P | 1 |
| Vavricka, SR | 1 |
| Gu, LY | 1 |
| Lin, WW | 1 |
| Chen, XY | 1 |
| Ge, ZZ | 1 |
| Li, XB | 1 |
| Hu, TH | 3 |
| Chuah, SK | 5 |
| Tai, WC | 3 |
| Chiu, YC | 3 |
| Wu, KL | 3 |
| Kuo, CM | 2 |
| Hu, ML | 3 |
| Krasz, S | 1 |
| Miehlke, S | 1 |
| Berning, M | 1 |
| Morgner, A | 1 |
| Labenz, J | 1 |
| Karczewska, E | 1 |
| Wojtas-Bonior, I | 1 |
| Sito, E | 1 |
| Zwolińska-Wcisło, M | 1 |
| Budak, A | 1 |
| Ermis, F | 2 |
| Akyuz, F | 2 |
| Uyanikoglu, A | 1 |
| Kurt, R | 1 |
| Pinarbasi, B | 1 |
| Nazik, H | 1 |
| Kaymakoglu, S | 1 |
| Mungan, Z | 2 |
| Basu, PP | 1 |
| Rayapudi, K | 1 |
| Pacana, T | 1 |
| Shah, NJ | 1 |
| Krishnaswamy, N | 1 |
| Flynn, M | 1 |
| Tsay, FW | 2 |
| Kadayifci, A | 1 |
| Ozcan, A | 1 |
| Emer, O | 1 |
| Seven, G | 1 |
| Cinar, K | 1 |
| Yakut, M | 1 |
| Idılman, R | 1 |
| Ozden, A | 1 |
| McNulty, CA | 1 |
| Lasseter, G | 1 |
| Shaw, I | 1 |
| Nichols, T | 1 |
| D'Arcy, S | 1 |
| Lawson, AJ | 1 |
| Glocker, E | 1 |
| Compare, D | 1 |
| Pilloni, PA | 1 |
| Ricciardiello, L | 1 |
| Loguercio, C | 1 |
| Chang, KC | 1 |
| Chou, YP | 2 |
| Chiu, KW | 2 |
| Chiou, SS | 1 |
| Shiotani, A | 1 |
| Bermejo, F | 3 |
| Almela, P | 2 |
| Modolell, I | 2 |
| Bory, F | 3 |
| Ortuño, J | 2 |
| Sánchez-Pobre, P | 2 |
| Khorrami, S | 2 |
| Franco, A | 2 |
| Tomas, A | 2 |
| Guerra, I | 1 |
| Lamas, E | 3 |
| Ponce, J | 2 |
| Calvet, X | 3 |
| Cuadrado-Lavín, A | 1 |
| Salcines-Caviedes, JR | 1 |
| Carrascosa, MF | 1 |
| Dierssen-Sotos, T | 1 |
| Cobo, M | 1 |
| Campos, MR | 1 |
| Ayestarán, B | 1 |
| Fernández-Pousa, A | 1 |
| González-Colominas, E | 1 |
| Aresti-Zárate, S | 1 |
| Hernández, M | 1 |
| Pascual, EL | 1 |
| Tursi, A | 1 |
| Picchio, M | 1 |
| Elisei, W | 1 |
| Jeong, MH | 1 |
| Chung, JW | 1 |
| Lee, SJ | 1 |
| Ha, M | 1 |
| Jeong, SH | 1 |
| Na, S | 1 |
| Na, BS | 1 |
| Park, SK | 1 |
| Kim, YJ | 1 |
| Kwon, KA | 1 |
| Ko, KI | 1 |
| Jo, Y | 1 |
| Hahm, KB | 1 |
| Jung, HY | 1 |
| Manfredi, M | 1 |
| Bizzarri, B | 1 |
| de'Angelis, GL | 1 |
| Turvey, SE | 1 |
| Leo, SH | 1 |
| Boos, A | 1 |
| Deans, GD | 1 |
| Prendiville, J | 1 |
| Crawford, RI | 1 |
| Senger, C | 1 |
| Conley, ME | 1 |
| Tilley, P | 1 |
| Junker, A | 1 |
| Janz, L | 1 |
| Azana, R | 1 |
| Hoang, L | 1 |
| Morton, TL | 1 |
| Buzás, GM | 1 |
| Kuo, YH | 1 |
| Liang, CM | 1 |
| Sereni, G | 1 |
| Azzolini, F | 1 |
| Camellini, L | 1 |
| Formisano, D | 1 |
| Decembrino, F | 1 |
| Iori, V | 1 |
| Tioli, C | 1 |
| Cavina, M | 2 |
| Di Mario, F | 1 |
| Bedogni, G | 1 |
| Sassatelli, R | 1 |
| Wang, SS | 1 |
| Liu, CJ | 1 |
| Chen, YH | 1 |
| Hsieh, MC | 1 |
| Tseng, HH | 2 |
| Ridola, L | 1 |
| Repici, A | 1 |
| Bruzzese, V | 1 |
| Cerqueira, RM | 1 |
| Correia, MR | 1 |
| Fernandes, CD | 1 |
| Vilar, H | 1 |
| Manso, MC | 1 |
| Qian, J | 1 |
| Ye, F | 1 |
| Zhang, J | 1 |
| Yang, YM | 1 |
| Tu, HM | 1 |
| Jiang, Q | 1 |
| Shang, L | 1 |
| Pan, XL | 1 |
| Fini, L | 2 |
| Daoud, Y | 1 |
| Grizzi, F | 1 |
| De Lorenzo, A | 1 |
| Di Renzo, L | 1 |
| McCartney, S | 1 |
| Bloom, S | 1 |
| Hsu, SJ | 1 |
| Luo, JC | 1 |
| Chang, WH | 1 |
| Hsu, YC | 1 |
| Tseng, CH | 1 |
| Tseng, PH | 1 |
| Yang, UC | 1 |
| Shun, CT | 1 |
| Seck, A | 1 |
| Burucoa, C | 1 |
| Dia, D | 1 |
| Mbengue, M | 1 |
| Onambele, M | 1 |
| Raymond, J | 1 |
| Breurec, S | 1 |
| Zocco, MA | 6 |
| Cremonini, F | 3 |
| Candelli, M | 5 |
| Nista, EC | 5 |
| Bartolozzi, F | 1 |
| Armuzzi, A | 2 |
| Cammarota, G | 8 |
| Santarelli, L | 3 |
| Wong, WM | 2 |
| Lam, SK | 1 |
| Fung, FM | 2 |
| Lai, KC | 2 |
| Hu, WH | 1 |
| Yee, YK | 3 |
| Xia, HH | 1 |
| Yuen, MF | 2 |
| Lorenzetti, R | 2 |
| Marignani, M | 1 |
| Angeletti, S | 1 |
| Ierardi, E | 3 |
| Morini, S | 7 |
| Asaumi, N | 2 |
| Masuda, K | 1 |
| Yoshida, C | 2 |
| Kiguchi, T | 1 |
| Niiya, M | 2 |
| Niiya, K | 2 |
| Tanimoto, M | 2 |
| Cazzato, IA | 1 |
| Gabrielli, M | 2 |
| Ojetti, V | 3 |
| Carloni, E | 2 |
| Gasbarrini, G | 6 |
| Perri, F | 1 |
| Festa, V | 1 |
| Merla, A | 1 |
| Barberani, F | 1 |
| Pilotto, A | 1 |
| Andriulli, A | 1 |
| Shibakura, M | 1 |
| Watanabe, Y | 2 |
| Aoyama, N | 3 |
| Shirasaka, D | 3 |
| Maekawa, S | 1 |
| Kuroda, K | 1 |
| Miki, I | 3 |
| Kachi, M | 1 |
| Fukuda, M | 1 |
| Wambura, C | 1 |
| Tamura, T | 3 |
| Kasuga, M | 3 |
| Zou, J | 1 |
| Yang, ZX | 1 |
| Qin, ZM | 1 |
| Cianci, R | 3 |
| Cannizzaro, O | 2 |
| Martino, A | 1 |
| Fedeli, P | 1 |
| Lecca, PG | 1 |
| Cesaro, P | 1 |
| Branca, G | 2 |
| Bosques-Padilla, FJ | 1 |
| Garza-González, E | 1 |
| Calderón-Lozano, IE | 1 |
| Reed-SanRoman, G | 1 |
| de Ariño Suárez, M | 1 |
| Valdovinos-Díaz, MA | 1 |
| Orozco-Gámiz, A | 1 |
| Blancas-Valencia, JM | 1 |
| Tamayo-de la Cuesta, JL | 1 |
| Dohden, K | 1 |
| Kaizaki, Y | 1 |
| Hosokawa, O | 1 |
| Hayashi, H | 1 |
| Hattori, M | 1 |
| Spanu, T | 1 |
| Schito, AM | 1 |
| Gasbarrini, GB | 2 |
| Fadda, G | 1 |
| Pignataro, G | 1 |
| Cazzato, A | 2 |
| Di Campli, C | 1 |
| Coelho, LG | 1 |
| Moretzsohn, LD | 1 |
| Vieira, WL | 1 |
| Gallo, MA | 1 |
| Passos, MC | 1 |
| Cindr, JM | 1 |
| Cerqueira, MC | 1 |
| Vitiello, L | 1 |
| Ribeiro, ML | 1 |
| Mendonça, S | 1 |
| Pedrazzoli-Júnior, J | 1 |
| Castro, LP | 1 |
| Lee, MG | 1 |
| Arthurs, M | 1 |
| Smikle, MF | 1 |
| Dowe, G | 1 |
| Levy, V | 1 |
| Barton, EN | 1 |
| Gatta, L | 1 |
| Perna, F | 3 |
| Ricci, C | 4 |
| Tampieri, A | 1 |
| Bernabucci, V | 1 |
| Iacopini, F | 1 |
| Crispino, P | 1 |
| Paoluzi, OA | 1 |
| Consolazio, A | 1 |
| Pica, R | 1 |
| Rivera, M | 1 |
| Palladini, D | 1 |
| Nardi, F | 1 |
| Paoluzi, P | 1 |
| McLoughlin, RM | 1 |
| O'Morain, CA | 1 |
| O'Connor, HJ | 1 |
| Matsumoto, Y | 2 |
| Morita, Y | 2 |
| Toyoda, M | 2 |
| Mitani, T | 2 |
| Miyachi, H | 2 |
| Kim, JS | 1 |
| Kim, N | 1 |
| Morena, F | 1 |
| Giannini, EG | 2 |
| Bilardi, C | 2 |
| Dulbecco, P | 2 |
| Mamone, M | 2 |
| Santi, ML | 2 |
| Testa, R | 2 |
| Mansi, C | 2 |
| Savarino, V | 2 |
| Chan, AO | 2 |
| Antos, D | 1 |
| Schneider-Brachert, W | 1 |
| Bästlein, E | 1 |
| Hänel, C | 1 |
| Haferland, C | 1 |
| Buchner, M | 1 |
| Meier, E | 1 |
| Trump, F | 1 |
| Stolte, M | 1 |
| Lehn, N | 1 |
| Bayerdörffer, E | 1 |
| Kang, MS | 1 |
| Park, DI | 1 |
| Yun, JW | 1 |
| Oh, SY | 1 |
| Yoo, TW | 1 |
| Park, JH | 1 |
| Kim, HJ | 1 |
| Cho, YK | 1 |
| Sohn, CI | 1 |
| Jeon, WK | 1 |
| Kim, BI | 1 |
| Ducons, J | 1 |
| Benito, LM | 2 |
| López-Rivas, L | 1 |
| Pabón, M | 1 |
| Olivares, D | 1 |
| Niv, Y | 1 |
| Bechor, J | 1 |
| Saad, RJ | 1 |
| Schoenfeld, P | 1 |
| Kim, HM | 1 |
| Chey, WD | 1 |
| Vakil, N | 1 |
| Yuan, Y | 1 |
| Thabane, L | 1 |
| Hunt, RH | 1 |
| Montalto, M | 1 |
| Pandolfi, F | 1 |
| Lauritano, EC | 1 |
| Santoro, M | 1 |
| Finizio, R | 2 |
| Lee, JH | 1 |
| Hong, SP | 1 |
| Kwon, CI | 1 |
| Phyun, LH | 1 |
| Lee, BS | 1 |
| Song, HU | 1 |
| Ko, KH | 1 |
| Hwang, SG | 1 |
| Park, PW | 1 |
| Rim, KS | 1 |
| Kim, S | 1 |
| Marzio, L | 1 |
| Coraggio, D | 1 |
| Capodicasa, S | 1 |
| Grossi, L | 1 |
| Cappello, G | 1 |
| Kinoshita, S | 1 |
| Okano, Y | 1 |
| Kumagai, S | 1 |
| Rokkas, T | 1 |
| Sechopoulos, P | 1 |
| Robotis, J | 1 |
| Wu, HM | 1 |
| Chen, TH | 1 |
| Liu, TY | 1 |
| Chiu, HM | 1 |
| Chang, CC | 1 |
| Chiang, H | 1 |
| Wu, MC | 1 |
| Spada, C | 1 |
| Carothers, JJ | 1 |
| Bruce, MG | 1 |
| Hennessy, TW | 1 |
| Bensler, M | 1 |
| Morris, JM | 1 |
| Reasonover, AL | 1 |
| Hurlburt, DA | 1 |
| Parkinson, AJ | 1 |
| Coleman, JM | 1 |
| McMahon, BJ | 1 |
| Saracino, I | 1 |
| Prieto-Bermejo, AB | 1 |
| Robledo-Andrés, P | 1 |
| Efrati, C | 1 |
| Maconi, G | 1 |
| Piglionica, D | 1 |
| Cannaviello, C | 1 |
| Panella, C | 1 |
| Chen, WY | 1 |
| Rispo, A | 1 |
| Di Girolamo, E | 1 |
| Cozzolino, A | 1 |
| Bozzi, R | 1 |
| Morante, A | 1 |
| Pasquale, L | 1 |
| Ortiz, V | 1 |
| Niño, P | 1 |
| Carneros, JA | 1 |
| García-Durán, F | 1 |
| O'Callaghan, E | 1 |
| Valer, MP | 1 |
| Fung, J | 1 |
| Hung, I | 1 |
| Van der Poorten, D | 1 |
| Page, RL | 1 |
| Ferguson, D | 1 |
| Cantu, M | 1 |
| Gigliotti, F | 1 |
| Lee, CC | 1 |
| Lee, VW | 1 |
| Chan, FK | 1 |
| Ling, TK | 1 |
| Peng, NJ | 1 |
| Lo, GH | 1 |
| Lu, CY | 1 |
| Lai, KH | 1 |
| Sakurai, N | 1 |
| Sano, M | 1 |
| Hirayama, F | 1 |
| Kuroda, T | 1 |
| Uemori, S | 1 |
| Moriguchi, A | 1 |
| Yamamoto, K | 1 |
| Ikeda, Y | 1 |
| Kawakita, T | 1 |
| Cuoco, L | 1 |
| Pirozzi, G | 1 |
| Arancio, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Two Rescue Therapies for Helicobacter Pylori Infection - A Multicenter Randomized Controlled Trial[NCT02547012] | 51 participants (Actual) | Interventional | 2013-11-30 | Completed | |||
| Personalized Treatment for Refractory H Pylori Infection[NCT02547025] | 126 participants (Actual) | Interventional | 2012-08-01 | Completed | |||
| A Prospective Randomized Trial of Levofloxacin-amoxicillin Triple Therapy vs. Levofloxacin-tetracycline Quadruple Therapy in Second-line Helicobacter Pylori Treatment[NCT02978157] | 102 participants (Actual) | Interventional | 2015-02-28 | Completed | |||
| "Phase 4, Prospective, Randomized Study Comparing 14-day Non-bismuth Quadruple Hybrid and Concomitant Therapies for Helicobacter Pylori Eradication in Settings With High Clarithromycin Resistance"[NCT01464060] | Phase 4 | 400 participants (Anticipated) | Interventional | 2011-09-30 | Recruiting | ||
| Comparative Study of the Levofloxacin-Based and Clarithromycin-Based Triple Therapy in First-Line Treatment for Helicobacter Pylori Eradication and Change of Gut Flora and Drug Susceptibility Before and After Treatment[NCT00816140] | Phase 4 | 432 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Comparison of the Efficacy of Clarithromycin-based Triple Therapy for 14 Days Versus Sequential Therapy for 10 Days in the First Line Therapy for Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial[NCT01607918] | Phase 4 | 1,300 participants (Anticipated) | Interventional | 2012-02-29 | Recruiting | ||
| Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Bismuth Quadruple Therapy in the Second Line and Third Line Therapy for Helicobacter Pylori Infection- A Multi-center Randomized Trial[NCT03148366] | Phase 3 | 560 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection- A Multi-center Randomized Trial[NCT01537055] | Phase 4 | 600 participants (Anticipated) | Interventional | 2012-02-29 | Recruiting | ||
| Comparison Between Hybrid, Reverse Hybrid, and Non-Bismuth Levofloxacin Quadruple Regimens for Helicobacter Pylori Infection in Egypt: A Randomized Controlled Trial[NCT04039412] | Phase 4 | 330 participants (Actual) | Interventional | 2018-06-01 | Completed | ||
| The Efficacy of 10-day Metronidazole and Levofloxacin Containing Sequential Therapy and 10-day Levofloxacin-containing Triple Therapy In Second Line Helicobacter Pylori Eradication Therapies[NCT02596620] | 164 participants (Actual) | Interventional | 2013-10-31 | Completed | |||
| Comparing the Efficacy and Impact on Gastrointestinal Microbiome of Reverse Hybrid Therapy and Bismuth Quadruple Therapy in Helicobacter Pylori Eradication[NCT02547038] | 352 participants (Actual) | Interventional | 2015-02-28 | Completed | |||
| Comparison of Hybrid and Bismuth Containing Quadruple Therapies for Helicobacter Pylori Eradication: a Randomized Controlled Trial[NCT02541864] | 330 participants (Actual) | Interventional | 2013-07-31 | Completed | |||
| Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection - a Randomized Controlled Trial (REHYTRI Study)[NCT02359435] | 440 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| Helicobacter Pylori Eradication in Mexico With a Levofloxacin-containing Scheme Versus Clarithromycin-based Triple Therapy: a Randomized, Open-label, Non-inferiority, Phase 3b Trial.[NCT02726269] | Phase 3 | 230 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| Comparison of the Efficacy of 14-day Sequential Therapy and 10-day Bismuth Quadruple Therapy in the Second Line Therapy for Helicobacter Pylori Infection: A Multi-center Randomized Trial[NCT03208426] | Phase 4 | 240 participants (Anticipated) | Interventional | 2017-10-01 | Recruiting | ||
| Phase IV Study Comparing the Duration of Sequential Therapy[NCT01042184] | Phase 4 | 900 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Community-based Helicobacter Pylori Eradication With Two Sequential Antibiotic Regimens for the Residents and Migrants From a High-risk Area for Gastric Cancer[NCT00155389] | Phase 4 | 5,000 participants (Anticipated) | Interventional | 2004-01-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02547012)
Timeframe: six weeks after the end of anti-H pylori therapy.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole+Amox+Levo+Tetra | 13 |
| Esomeprazole+Amox+Levo | 21 |
Number of participants with negative H pylori status in follow-up tests as a measure of successful eradication (NCT02978157)
Timeframe: six weeks after the end of anti-H pylori therapy.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole+Amox+Levo | 36 |
| Esomeprazole+Bismuth+Tetra+Levo | 49 |
Questionnaire to measure the number of Participants with Treatment-Emergent Adverse Events (NCT04039412)
Timeframe: 10-14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| (1) Reverse Hybrid Regimen | 49 |
| (2) Hybrid Regimen | 58 |
| (3) Levofloxacin Quadruple Regimen | 44 |
Measuring the curative rate of each regimen by a fecal antigen test (NCT04039412)
Timeframe: 40-44 days
| Intervention | Participants (Count of Participants) |
|---|---|
| (1) Reverse Hybrid Regimen | 102 |
| (2) Hybrid Regimen | 101 |
| (3) Levofloxacin Quadruple Regimen | 91 |
Questionnaire to evaluate the compliance with each treatment regimen (NCT04039412)
Timeframe: 10-14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| (1) Reverse Hybrid Regimen | 109 |
| (2) Hybrid Regimen | 107 |
| (3) Levofloxacin Quadruple Regimen | 108 |
Successful eradication of H. pylori is defined as (1) negative results of both rapid urease test and histology, or (2) a negative result of urea breath test at 4 weeks. (NCT02596620)
Timeframe: Negative results of H.pylori 4 weeks after eradication
| Intervention | percentage of eradication (Number) |
|---|---|
| Sequential Therapy | 91.4 |
| Triple Therapy | 81.5 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (Number of Participants With Complete Eradication of Helicobacter Pylori) (NCT02547038)
Timeframe: sixth week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Pantoprazole+Bismuth+Tetra+Metro | 169 |
| (Panto+Amox+Clar+Metr)+(Panto+Amox) | 170 |
Repeated endoscopy with rapid urease test, histological examination and culture or urea breath tests are conducted to assess H. pylori status. (NCT02541864)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Pantoprazole+Bismuth+Tetra+Metro | 154 |
| Hybrid Therapy | 154 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02359435)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Reverse Hybrid Therapy | 206 |
| Standard Triple Therapy | 191 |
22 reviews available for ofloxacin and Helicobacter Infections
| Article | Year |
|---|---|
A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication).
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Dose-Response Relationship, Drug; Drug | 2013 |
Second and third line treatment options for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolo | 2014 |
[The new aspects of the eradication of Helicobacter pylori and the importance of bacterial resistance].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Administration Schedule; Drug Res | 2008 |
[Effectiveness and safety of proton pump inhibitor and levofloxacin based first-line triple therapy in the eradication of Helicobacter pylori: a meta-analysis].
Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Huma | 2008 |
Helicobacter pylori: diagnosis and treatment.
Topics: Amoxicillin; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroq | 2009 |
Helicobacter pylori eradication therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Bac | 2010 |
Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.
Topics: Anti-Infective Agents; Aza Compounds; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Re | 2010 |
Treatment of Helicobacter pylori infection: the past and the future.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helico | 2010 |
[Current perspective of the resistance of Helicobacter pylori strains to antimicrobial drugs].
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helico | 2010 |
[New options for helicobacter pylori antibiotic treatment].
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Dose-Response Relationship, Drug; Drug Administr | 2011 |
[Current value of quinolones in Helicobacter pylori therapy].
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroq | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
Successful approach to treatment of Helicobacter bilis infection in X-linked agammaglobulinemia.
Topics: Adolescent; Adult; Agammaglobulinemia; Anti-Bacterial Agents; Azithromycin; beta-Lactams; Chronic Di | 2012 |
[Helicobacter pylori - 2012].
Topics: Algorithms; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Dr | 2012 |
Modified sequential therapy regimens for Helicobacter pylori eradication: a systematic review.
Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Huma | 2013 |
Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Chi-Square Distribution; Drug Administration Schedu | 2012 |
Treatment of H. pylori infection: a review.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Bismuth; Clarithromycin; Fluoroquinolones; Furazolidone | 2005 |
Eradication of Helicobacter pylori: recent advances in treatment.
Topics: Drug Resistance, Bacterial; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Levo | 2005 |
Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure.
Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter | 2006 |
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast | 2006 |
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast | 2006 |
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast | 2006 |
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast | 2006 |
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast | 2006 |
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast | 2006 |
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast | 2006 |
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast | 2006 |
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast | 2006 |
Third-line rescue therapy for Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Doxycycline; Furazolidone; Helicobacter Infections; Helicobacter pylori; Huma | 2006 |
[Treatment for Helicobacter pylori: current criteria].
Topics: Alkylating Agents; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug A | 2007 |
63 trials available for ofloxacin and Helicobacter Infections
| Article | Year |
|---|---|
Antofloxacin-based bismuth quadruple therapy is safe and effective in Helicobacter pylori eradication: A prospective, open-label, randomized trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Hel | 2021 |
Efficacy and Safety of Antofloxacin-Based Triple Therapy for Helicobacter pylori Eradication Failure in China.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; China; Drug Therapy, Combination; Esomepraz | 2022 |
Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Resistance, Bacterial; Drug Therapy, | 2013 |
Efficacy of two levofloxacin-containing second-line therapies for Helicobacter pylori: a pilot study.
Topics: Adult; Aged; Anti-Bacterial Agents; Antigens, Bacterial; Drug Therapy, Combination; Drug-Related Sid | 2013 |
[Efficacy of levofloxacin-based triple therapy as second-line Helicobacter pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; | 2008 |
Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; B | 2009 |
Failure of Helicobacter pylori treatment after regimes containing clarithromycin: new practical therapeutic options.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 2008 |
Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Endoscopy, Gastrointestinal; Esomeprazo | 2009 |
Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Endoscopy, Gastrointestinal; Esomeprazo | 2009 |
Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Endoscopy, Gastrointestinal; Esomeprazo | 2009 |
Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Endoscopy, Gastrointestinal; Esomeprazo | 2009 |
Efficacy of a 7-day course of furazolidone, levofloxacin, and lansoprazole after failed Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Infective Agents; Dose-Response Relations | 2009 |
Clarithromycin-amoxycillin-containing triple therapy: a valid empirical first-line treatment for Helicobacter pylori eradication in Hong Kong?
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomepra | 2009 |
The modified sequential treatment regimen containing levofloxacin for Helicobacter pylori eradication in Turkey.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2009 |
Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2010 |
Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2010 |
Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2010 |
Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2010 |
Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; C | 2010 |
[Levofloxacin-based triple therapy for first-line Helicobacter pylori eradication treatment: a multi-central, randomized, controlled clinical study].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Drug Therapy, Combination; Female | 2010 |
Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design.
Topics: Adult; Anti-Bacterial Agents; Clarithromycin; Cross-Over Studies; Drug Administration Schedule; Drug | 2010 |
Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective A | 2010 |
Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Co | 2010 |
Comparison of the once-daily levofloxacin-containing triple therapy with the twice-daily standard triple therapy for first-line Helicobacter pylori eradication: a prospective randomised study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administrat | 2010 |
Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Drug Costs; Drug Resistance, Bacteri | 2010 |
Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Drug Costs; Drug Resistance, Bacteri | 2010 |
Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Drug Costs; Drug Resistance, Bacteri | 2010 |
Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Drug Costs; Drug Resistance, Bacteri | 2010 |
Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Ch
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2010 |
Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Breath Tests; Cytochrome P-450 CY | 2011 |
Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Breath Tests; Cytochrome P-450 CY | 2011 |
Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Breath Tests; Cytochrome P-450 CY | 2011 |
Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Breath Tests; Cytochrome P-450 CY | 2011 |
Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Diarrhea; Double-Blind Method; Drug | 2011 |
Quadruple therapy with medications containing either rufloxacin or furazolidone as a rescue regimen in the treatment of Helicobacter pylori-infected dyspepsia patients: a randomized pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer | 2011 |
Randomized comparison of two nonbismuth-containing rescue therapies for Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, C | 2011 |
Second-line levofloxacin-based triple therapy's efficiency for Helicobacter pylori eradication in patients with peptic ulcer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; D | 2011 |
A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2011 |
Comparison of levofloxacin-containing sequential and standard triple therapies for the eradication of Helicobacter pylori.
Topics: Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Dose-Response Relationship, D | 2012 |
Assessment of Helicobacter pylori eradication rate of triple combination therapy containing levofloxacin.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Helicobacter Infection | 2011 |
Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Dr | 2012 |
Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Administration Schedule; Drug Therapy, Combina | 2012 |
Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line Helicobacter pylori eradication: a single-blind randomized clinical trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Ther | 2012 |
Efficacy and tolerability of a third-line, levofloxacin-based, 10-day sequential therapy in curing resistant Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Drug Administration Schedule; Drug Resistance, Bacterial; | 2012 |
Helicobacter pylori infection: sequential therapy followed by levofloxacin-containing triple therapy provides a good cumulative eradication rate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combin | 2012 |
The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment--a pilot study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Drug Therapy, Combination; Female; He | 2012 |
Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy: a randomized controlled trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; | 2013 |
Levofloxacin-containing triple and sequential therapy or standard sequential therapy as the first line treatment for Helicobacter pylori eradication in China.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Breath Tests; China; Drug Therapy, Combination; Fema | 2012 |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2013 |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2013 |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2013 |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2013 |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2013 |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2013 |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2013 |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2013 |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2013 |
Levofloxacin based regimens for the eradication of Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Female; Helicobacter Infections; Helicobacter pylori | 2002 |
Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; | 2003 |
Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial.
Topics: Adolescent; Adult; Aged; Antacids; Anti-Infective Agents; Bismuth; Drug Therapy, Combination; Female | 2003 |
Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2003 |
[Laboratory and clinical study of levofloxacin against Helicobacter pylori].
Topics: Adolescent; Adult; Aged; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter p | 2003 |
High-dose versus low-dose clarithromycin in 1-week triple therapy, including rabeprazole and levofloxacin, for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infect | 2004 |
Open, randomized multicenter comparative trial of rabeprazole, ofloxacin and amoxicillin therapy for Helicobacter pylori eradication: 7 vs. 14 day treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2004 |
One-week once-daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Drug Administration Schedule; Drug Therapy, | 2005 |
Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan.
Topics: Adult; Aged; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Heli | 2005 |
A study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Infective Agents; Antitrichomon | 2006 |
Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infec | 2006 |
7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Dose-Response Relationship, Drug; D | 2006 |
[Levofloxacin-azithromycin combined triple therapy for Helicobacter pylori eradication].
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Drug Therapy, Combination; Female; Helicobacter Infectio | 2006 |
Third-line rescue therapy with levofloxacin after two H. pylori treatment failures.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, C | 2006 |
Rifaximin-based regimens for eradication of Helicobacter pylori: a pilot study.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Clarithromycin; Drug Therapy, Combination; Dyspepsia | 2006 |
Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal A | 2006 |
Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Biopsy; Clarithromycin; Drug Therapy, Combination; E | 2006 |
Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures.
Topics: Aged; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacte | 2006 |
Levofloxacin- vs. ranitidine bismuth citrate-containing therapy after H. pylori treatment failure.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter I | 2007 |
First-line triple therapy with levofloxacin for Helicobacter pylori eradication.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combinati | 2007 |
Helicobacter pylori eradication with either quadruple regimen with lactoferrin or levofloxacin-based triple therapy: a multicentre study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; | 2007 |
Levofloxacin-containing triple therapy to eradicate the persistent H. pylori after a failed conventional triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; | 2007 |
Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients.
Topics: Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Therapy, Combination; Endosco | 2008 |
Clinical trial: levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Drug Therapy, Combination; Esomeprazo | 2007 |
Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Dr | 2007 |
Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2000 |
64 other studies available for ofloxacin and Helicobacter Infections
| Article | Year |
|---|---|
Education and imaging. Gastrointestinal: colonic mucosa-associated lymphoid tissue lymphoma regressed by levofloxacin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clar | 2013 |
Novel agent for Helicobacter pylori infection management.
Topics: Animals; Anti-Bacterial Agents; Escherichia coli; Female; Galactosylceramides; Gastric Mucosa; Gastr | 2013 |
Letter: levofloxacin resistance - a challenge for the treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combin | 2017 |
Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Case-Control Studies; Chi-Square Distribution; Clar | 2008 |
Seven-day PPI-triple therapy with levofloxacin is very effective for Helicobacter pylori eradication.
Topics: Amoxicillin; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; | 2009 |
Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Asian People; Child; | 2009 |
Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration | 2010 |
Helicobacter pylori: antibiotic resistance and treatment options.
Topics: Amoxicillin; Anti-Bacterial Agents; Asian People; Clarithromycin; Drug Resistance, Multiple, Bacteri | 2009 |
How to manage Helicobacter pylori after sequential therapy failure?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Child; Cli | 2010 |
Antibiotic resistance of Helicobacter pylori in Israeli children.
Topics: Adolescent; Amoxicillin; Analysis of Variance; Anti-Bacterial Agents; Biopsy; Chi-Square Distributio | 2010 |
A new second-line sequential regimen for Helicobacter pylori eradication based on levofloxacin: a pilot study.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Female; Helicobacter Infections; Helicobacter pylori | 2010 |
Clarithromycin or levofloxacin in the sequential therapy for H. pylori eradication?
Topics: Adolescent; Adult; Aged; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; | 2010 |
Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Drug Administration Schedule; Drug Therapy, Combination; E | 2010 |
In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.
Topics: Amino Acid Substitution; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Clarithro | 2010 |
[A case of mucosa-associated lymphoid tissue lymphoma with penicillin allergy successfully treated with levofloxacin, minomycin and rabeprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Biopsy; Drug Hypersensitivity; Female; Helicobacter Infecti | 2010 |
Resistance of Helicobacter pylori to antibiotics from 2000 to 2009 in Shanghai.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; China; Clarithromycin; Drug Resis | 2010 |
Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies.
Topics: Adult; Clarithromycin; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Female; Genotype; Helicobac | 2011 |
Levofloxacin in first-line eradication regimens for Helicobacter pylori: better test antibiotic susceptibility before treating.
Topics: Anti-Bacterial Agents; Clarithromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; | 2011 |
Sequential therapy for Helicobacter pylori eradication: is levofloxacin better?
Topics: Anti-Bacterial Agents; Clarithromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; | 2011 |
[Repetition of Helicobacter cinaedi infections during chemotherapy for malignant lymphoma].
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Cefozopran; Cephalospor | 2010 |
Primary resistance of Helicobacter pylori to levofloxacin and moxifloxacine in Iran.
Topics: Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Female; Flu | 2012 |
[Regional difference of antibiotic resistance of helicobacter pylori strains in Korea].
Topics: Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Ciprofloxacin; Clarithromycin; Drug | 2011 |
High Helicobacter pylori resistance to metronidazole but zero or low resistance to clarithromycin, levofloxacin, and other antibiotics in Malaysia.
Topics: Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Multiple, Bacterial; Female; He | 2011 |
Application of levofloxacine in the second phase of sequential therapy regimen for Helicobacter pylori eradication: is it a good choice?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2011 |
Helicobacter pylori eradication by sitafloxacin-lansoprazole combination and sitafloxacin pharmacokinetics in Mongolian gerbils and its in vitro activity and resistance development.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Bacterial Agents; Drug Combinations; Fluoroqu | 2011 |
Primary and secondary clarithromycin, metronidazole, amoxicillin and levofloxacin resistance to Helicobacter pylori in southern Poland.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Multiple, Bacterial; Hel | 2011 |
Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered?
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Dyspepsia; Endoscopy; England; Fe | 2012 |
Letter: third-line rescue therapy with levofloxacin after failure of two treatments to eradicate Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter | 2012 |
Which Therapy for Helicobacter pylori Infection?
Topics: Anti-Bacterial Agents; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Ofloxacin | 2012 |
Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Schedul | 2013 |
Recurrence of Helicobacter pylori After Eradication in Patients with Peptic Ulcer.
Topics: Amoxicillin; Anti-Bacterial Agents; Female; Helicobacter Infections; Helicobacter pylori; Humans; Ma | 2012 |
[Comparison of rifabutin- and levofloxacin-based third-line rescue therapies for Helicobacter pylori].
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Drug Resistance, B | 2012 |
Guide regarding choice of second-line therapy to obtain a high cumulative cure rate.
Topics: Anti-Bacterial Agents; Female; Helicobacter Infections; Humans; Male; Ofloxacin | 2012 |
Efficacy of a therapeutic strategy for eradication of Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Breath Tests; Clarithromycin; Comorbidity; | 2012 |
Cumulative Helicobacter pylori eradication therapy in obese patients undergoing gastric bypass surgery.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Th | 2013 |
Primary antibiotic resistance and associated mechanisms in Helicobacter pylori isolates from Senegalese patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Clarithromycin; DNA Gyrase; Drug Resistance | 2013 |
A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer | 2003 |
[Helicobacter pylori eradication based upon a drug sensitivity test effectively increased platelet count in a patient with refractory idiopathic thrombocytopenic purpura].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Helicobacter Infections; Helicobacte | 2003 |
Secondary eradication of Helicobacter pylori was effective against refractory idiopathic thrombocytopenic purpura.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Blood Platelets; Drug Therapy, Combi | 2003 |
Levofloxacin based triple therapy as a second-line treatment after failure of helicobacter pylori eradication with standard triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; | 2003 |
Regression of rectal mucosa-associated lymphoid tissue lymphoma but persistence of Helicobacter pylori infection of gastric mucosa after administration of levofloxacin: report of a case.
Topics: Anti-Infective Agents; Female; Gastrointestinal Hemorrhage; Helicobacter Infections; Helicobacter py | 2004 |
High levels of dual resistance to clarithromycin and metronidazole and in vitro activity of levofloxacin against Helicobacter pylori isolates from patients after failure of therapy.
Topics: Clarithromycin; Drug Resistance; Drug Therapy, Combination; Helicobacter Infections; Helicobacter py | 2004 |
New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Infective Agents, Local; | 2005 |
Antibiotic sensitivity of Helicobacter pylori in Jamaica.
Topics: Aged; Breath Tests; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori | 2004 |
A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses.
Topics: Amoxicillin; Anti-Bacterial Agents; Drug Evaluation; Drug Resistance, Bacterial; Drug Therapy, Combi | 2005 |
Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA, Bacte | 2005 |
Rescue therapy with levofloxacin after multiple H. pylori treatment failures.
Topics: Anti-Bacterial Agents; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Ofloxacin | 2005 |
In vitro activity of levofloxacin against Helicobacter pylori isolates from patients after treatment failure.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Drug Utilization; Fema | 2006 |
Helicobacter pylori treatment: a practical approach.
Topics: Bismuth; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; | 2006 |
Levofloxacin-based rescue regimens after Helicobacter pylori treatment failure: how strong is the evidence?
Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Huma | 2006 |
[The efficacy of levofloxacin based triple therapy for Helicobacter pylori eradication].
Topics: Adult; Aged; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Heli | 2006 |
Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bacterial Proteins; Breath Tests; Drug Resistance, Bacter | 2006 |
Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Proteins; DNA Gyrase; DNA Mutationa | 2006 |
Triple levofloxacin-based rescue therapy is an accepted empirical third-line treatment.
Topics: Amoxicillin; Ampicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Dru | 2006 |
A community-based study of Helicobacter pylori therapy using the strategy of test, treat, retest, and re-treat initial treatment failures.
Topics: Anti-Bacterial Agents; Delivery of Health Care; Drug Therapy, Combination; Female; Helicobacter Infe | 2006 |
The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Female; | 2007 |
Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Drug Resistance; | 2007 |
Levofloxacin in first-line treatment of Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobac | 2007 |
The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice.
Topics: Adult; Aged; Amoxicillin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter p | 2007 |
An alternative salvage regimen for Helicobacter pylori-resistant patients with heart failure.
Topics: Amoxicillin; Anti-Bacterial Agents; Comorbidity; Drug Therapy, Combination; Heart Failure; Helicobac | 2008 |
Levofloxacin-resistant Helicobacter pylori in Hong Kong.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; DNA Gyrase; DNA Mutational Analysis; DNA, Bacter | 2008 |
Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon | 2008 |
Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon | 2008 |
Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon | 2008 |
Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon | 2008 |
Synthesis and structure-activity relationships of 7-(2-aminoalkyl)morpholinoquinolones as anti-Helicobacter pylori agents.
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Drug Stability; Fluoroquinolones; Gerbillinae; Helicob | 1998 |
Helicobacter pylori eradication: do we have another ace up our sleeve?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adult; Anti-Infective Agents; Be | 2001 |